Type 2 & other diabetes

Blood glucose trajectories in diabetes patients receiving CAPDCA model of personalised patient education: A cluster randomised controlled trial

Diabetes Obes MetabPublished Cluster randomised controlled trial

Authors' conclusion

The CAPDCA model can effectively improve the control of HbA1c. The analysis of influencing factors of different trajectories suggested that the model was suitable for patients with different ages, genders, education levels, and disease duration. Further studies would be needed in exploring the application to various diseases and integrating the CAPDCA model with technologies such as artificial intelligence.

Study context

Population
Patients with T2D in 6 community health centres
Participants
178 patients
Comparison
CAPDCA model education vs traditional education
  • Interventionn = 90
  • Controln = 88reference
Methodological details6 community health centres
  • 6 community health centres

Primary result

As reported in the abstract

HbA1c · 18 months

T

6.356

P < 0.01

lower HbA1c with Intervention

T (HbA1c reduction)

−6.117

P < 0.01

greater HbA1c reduction with Intervention

Further findings

FBG trajectories (Group-Based Trajectory Model (GBTM))

Two trajectories: Steady descent and rebound; influenced by baseline HbA1c

2 h-PG trajectories (GBTM)

Three trajectories: High BG-high descent, Medium BG-low descent, low BG-high descent; influenced by baseline HbA1c and medication adherence

Blood glucose post-intervention

All trajectories reached clinically target ranges post-intervention
Age, gender, education and disease duration not significantly associated with trajectories

Original publication

Blood glucose trajectories in diabetes patients receiving CAPDCA model of personalised patient education: A cluster randomised controlled trial. Diabetes Obes Metab. Published 14 September 2025. doi:10.1111/dom.70119

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.